A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
about
Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the futureThe evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.Current and evolving features in the clinical management of haemophiliaPrinciples of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyRandomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.Prophylaxis in older Canadian adults with hemophilia A: lessons and more questionsPatient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia AAdherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A.How much medicine do spine surgeons need to know to better select and care for patients?Monitoring rFVIII prophylaxis dosing using global haemostasis assays.Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.Tertiary prophylaxis in adults: is there a rationale?Octocog alfa (Advate®): a guide to its use in hemophilia A.The burden of bleeding in haemophilia: is one bleed too many?Considerations in individualizing prophylaxis in patients with haemophilia A.Factor VIII therapy for hemophilia A: current and future issues.Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.Prophylaxis in real life scenarios.Methods for individualising factor VIII dosing in prophylaxis.Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.Managing chronic pain in adults with haemophilia: current status and call to action.Various regimens for prophylactic treatment of patients with haemophilia.Individualizing prophylaxis in hemophilia: a review.Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol.The current status of prophylactic replacement therapy in children and adults with haemophilia.Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia AProphylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).Prevention of bleeding in hemophilia patients with high-titer inhibitors.Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials.PK-guided personalized prophylaxis with Nuwiq(®) (human-cl rhFVIII) in adults with severe haemophilia A.BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics.Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products.Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq(®) ) in adults with severe haemophilia A: efficacy and safety.The association between health utility and joint status among people with severe haemophilia A: findings from the KAPPA register.Social/economic costs and quality of life in patients with haemophilia in Europe.Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study.
P2860
Q26853631-C6250BBB-E522-4ED1-B199-64924C6B8CC0Q30249256-C445743A-ED67-4D82-802F-96A5B9EC638DQ30958570-A05D52AF-96F4-4051-94B1-3539221B54CBQ33708976-56269747-0C69-46CE-BA63-4F3DBB6230DBQ34416394-00122D21-E760-453F-A435-4692AB6BC276Q34436796-1E8071D9-3846-48C1-842E-32A49D9E33B2Q35091077-C55D4C2B-A1F0-4F44-AFC9-090D2754A455Q35209354-F6BAFE52-066C-44B3-B519-E128CCFF82A5Q36000862-BDF41729-E9F0-467E-AD24-BDEC7CEDD551Q36189452-71C60FBA-950C-4D0F-B03D-34325FB9555CQ36460722-933793DE-1693-4E33-8A14-ED4602FFFEEDQ36788113-6DEB2D96-B597-44A6-8F3E-D226E147535AQ37489013-8A845DF3-0517-4124-AFEC-2D2399B08B85Q38008021-CF2B5683-1912-4980-A876-3639205408B9Q38013763-7472ADA9-1074-470C-AA77-E19D1A2707C2Q38023600-D9009CD3-9BCE-43B0-9AD5-C855BEF496EAQ38182702-C9538B8B-98FC-436C-AE59-E426324026B8Q38203021-B7205C68-D58C-45D9-8859-2D0C8EA95607Q38203350-7D088AF5-641D-4811-8F13-B39F1328D0C5Q38205211-B16466FD-26C0-4C8B-84AC-BB020CB3322EQ38206859-523A4BB9-7A9A-405B-81A3-8D3F94564A48Q38222572-4EEA33CB-B102-48D8-8CCC-B2C516305460Q38227605-2525EC9D-5475-492D-9343-387BA022CBEBQ38255960-A3A73228-7817-47B6-9DEB-D8A64613862BQ38308200-43EC3A83-FCCE-4361-80A6-3A33BFECD869Q38323857-55F484F5-E28E-4676-A524-F3140E278FF3Q38376784-A18B6AD1-77C5-4603-85FA-33CCEC38F33DQ38394904-E773D091-1669-432C-BF30-AD290CF4198DQ38408739-5316F6EA-28D6-49B5-B621-5D5A359AE558Q38418489-28072DBE-CAA4-48CC-9D06-5D928563C42EQ38456352-3C6F1DFD-C09D-4A5C-9CA4-BA03D1C81045Q38590269-8B916238-6787-4160-BCE8-F2B423AB2A4CQ38705742-F7C4F62A-62D9-4E04-93E8-84764480F9D4Q38725317-CD4E4660-3C68-45E2-BFE4-7E51B58327F6Q38739383-1273ECBF-F7AE-4A64-B755-41464AE1C867Q38764214-5633FAEE-FC89-4878-AB8B-FF7BB1C27D35Q38840145-A17FA0BE-DE95-4B22-B3E3-5B89BD667889Q38844972-A38E410E-C263-4177-9205-55EC8D476092Q38885402-5991C0A3-C534-4CB5-B180-5F03359E0569Q38888065-AC6FE6EB-833A-4D68-9C0C-C6C3AF61B7A1
P2860
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
A randomized comparison of two ...... nts in hemophilia A management
@ast
A randomized comparison of two ...... nts in hemophilia A management
@en
type
label
A randomized comparison of two ...... nts in hemophilia A management
@ast
A randomized comparison of two ...... nts in hemophilia A management
@en
prefLabel
A randomized comparison of two ...... nts in hemophilia A management
@ast
A randomized comparison of two ...... nts in hemophilia A management
@en
P2093
P2860
P1476
A randomized comparison of two ...... nts in hemophilia A management
@en
P2093
A Hellmann
L A Valentino
Prophylaxis Study Group
P2860
P304
P356
10.1111/J.1538-7836.2011.04611.X
P577
2012-03-01T00:00:00Z